Literature DB >> 32544255

From NAFLD to MAFLD: Implications of a premature change in terminology.

Zobair M Younossi1,2, Mary E Rinella3, Arun Sanyal4, Stephen A Harrison5, Elizabeth Brunt6, Zachary Goodman1,2, David E Cohen7, Rohit Loomba8.   

Abstract

The term nonalcoholic fatty liver disease (NAFLD) was initially introduced by Schaffner in 1986. NAFLD is a clinical entity characterized by the presence of hepatic steatosis affecting at least 5% of hepatocytes in individuals who consume little or no alcohol and who do not have a secondary cause of hepatic steatosis such as viral hepatitis, medications (such as tamoxifen, amiodarone and methotrexate, among others), or lipodystrophy. This article is protected by copyright. All rights reserved.

Entities:  

Year:  2020        PMID： 32544255     DOI： 10.1002/hep.31420

Source DB:  PubMed          Journal:  Hepatology        ISSN： 0270-9139            Impact factor:   17.425


  59 in total

1.  Gut microbiome in liver pathophysiology and cholestatic liver disease.

Authors:  Shengmin Yan; Xiao-Ming Yin
Journal:  Liver Res       Date:  2021-08-08

2.  Changing Nomenclature from Nonalcoholic Fatty Liver Disease to Metabolic Dysfunction-Associated Fatty Liver Disease - Not Only Premature But Also Confusing.

Authors:  Ajay Duseja; Sunil Taneja
Journal:  J Clin Exp Hepatol       Date:  2020-08-09

3.  Clinical and Histologic Features of Patients with Biopsy-Proven Metabolic Dysfunction-Associated Fatty Liver Disease.

Authors:  Shang-Chin Huang; Hau-Jyun Su; Jia-Horng Kao; Tai-Chung Tseng; Hung-Chih Yang; Tung-Hung Su; Pei-Jer Chen; Chun-Jen Liu
Journal:  Gut Liver       Date:  2021-05-15       Impact factor: 4.519

Review 4.  Intestinal Barrier and Permeability in Health, Obesity and NAFLD.

Authors:  Piero Portincasa; Leonilde Bonfrate; Mohamad Khalil; Maria De Angelis; Francesco Maria Calabrese; Mauro D'Amato; David Q-H Wang; Agostino Di Ciaula
Journal:  Biomedicines       Date:  2021-12-31

Review 5.  Emerging therapeutic approaches for the treatment of NAFLD and type 2 diabetes mellitus.

Authors:  Daniel Ferguson; Brian N Finck
Journal:  Nat Rev Endocrinol       Date:  2021-06-15       Impact factor: 43.330

6.  A Combination of Geniposide and Chlorogenic Acid Combination Ameliorates Nonalcoholic Steatohepatitis in Mice by Inhibiting Kupffer Cell Activation.

Authors:  Xin Xin; Yue Jin; Xin Wang; Beiyu Cai; Ziming An; Yi-Yang Hu; Qin Feng
Journal:  Biomed Res Int       Date:  2021-05-13       Impact factor: 3.411

Review 7.  Effect of Microalgae and Macroalgae Extracts on Non-Alcoholic Fatty Liver Disease.

Authors:  Maitane González-Arceo; Saioa Gómez-Zorita; Leixuri Aguirre; María P Portillo
Journal:  Nutrients       Date:  2021-06-11       Impact factor: 5.717

8.  Telemonitoring-Supported Exercise Training in Employees With Metabolic Syndrome Improves Liver Inflammation and Fibrosis.

Authors:  Sven Haufe; Katharina L Hupa-Breier; Pauline Bayerle; Hedwig T Boeck; Simone Rolff; Thorben Sundermeier; Arno Kerling; Julian Eigendorf; Momme Kück; Alexander A Hanke; Ralf Ensslen; Lars Nachbar; Dirk Lauenstein; Dietmar Böthig; Denise Hilfiker-Kleiner; Meike Stiesch; Christoph Terkamp; Heiner Wedemeyer; Axel Haverich; Uwe Tegtbur
Journal:  Clin Transl Gastroenterol       Date:  2021-06-18       Impact factor: 4.488

9.  Application of a Novel Prediction Model for Predicting 2-Year Risk of Non-Alcoholic Fatty Liver Disease in the Non-Obese Population with Normal Blood Lipid Levels: A Large Prospective Cohort Study from China.

Authors:  Liwei Ji; Xintian Cai; Yang Bai; Tao Li
Journal:  Int J Gen Med       Date:  2021-06-28

10.  Lean non-alcoholic fatty liver disease and associated metabolic disturbance: A Saudi Arabian cross-sectional study.

Authors:  Yasir Mohammed Khayyat
Journal:  Physiol Rep       Date:  2021-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.